Epanova NDA accepted, but market may be swim against the tide
This article was originally published in Scrip
Executive Summary
With the US FDA's acceptance of AstraZeneca's new drug application (NDA) for Epanova, a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils under investigationas a treatment for severe hypertriglyceridaemia – triglyceride levels greater than or equal to 500mg/dL – the UK drug maker has taken another step closer to bolstering its cardiovascular franchise.